Clinical trial

Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced…

NCT00305825 · University of California, San Francisco, Other · Completed

Key facts

NCT number NCT00305825
Title Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
Official title A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer
Lead sponsor University of California, San Francisco, Other
Collaborators National Cancer Institute (NCI) NIH Memorial Sloan Kettering Cancer Center
Status Completed
Phase Phase 2
Study type Interventional
Conditions Breast Cancer
Intervention type Biological, Drug
Interventions bevacizumab, letrozole
Enrollment 43
Start date Aug 1, 2004
Primary completion May 30, 2006
Completion May 24, 2016
First posted Mar 22, 2006
Last update posted Aug 31, 2017
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies